Suggested framework for consideration of eculizumab discontinuation in CM-TMA.⁺The role of complement inhibitor therapy and discontinuation is less clear in the setting of these “noncomplement” variants. ∗Note that the current study had small numbers of patients with variants in these genes, which should be considered when making decisions regarding complement inhibitor duration.